Diary - News
All news 1st patient randomized with Transgene Pexa-Vec
Transgene S.A. today announced the initiation of a multinational, randomized Phase 3 open label study with the oncolytic immunotherapy,
Pexa-Vec, in patients with advanced liver cancer, also known as hepatocellular carcinoma (HCC).
This trial is being led by Transgene’s partner, SillaJen, Inc.
The trial is evaluating the use of Pexa-Vec to treat HCC patients who are eligible for treatment with sorafenib (Nexavar®), the only approved drug for advanced HCC.
Read the press release
